drugset / Trial / NCT04291703
STOP-T1D Low-Dose (ATG)
Phase 2
Terminated
2 enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
RandomizedParallel-groupTriple-blindPrevention
Summary
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D. This study did not meet enrollment targets and was terminated approximately 13 months after the first participant enrolled.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2024-12-17
- Completion
- 2024-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 2 mg/kg | Intravenous |